Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Adjuvant Therapy in HER2+ Node-Negative Breast Cancer
NCT05841381Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2023
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of pyrotinib in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Disease free survival at 5 years. Planned start May 2023; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05841381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841381.